Scancell - Articles and news items

Scancell preparing SCIB2 for clinical study in lung cancer

Industry news / 13 October 2016 / Niamh Louise Marriott, Digital Content Producer

Scancell intends to develop its SCIB2 ImmunoBody for the treatment of non-small cell lung cancer (NSCLC) in combination with a checkpoint inhibitor…

SCIB1 continues to deliver encouraging survival data in melanoma

Industry news / 6 July 2016 / Victoria White, Digital Content Producer

Scancell has provided an update from the SCIB1 Phase I/II clinical trial in malignant melanoma, the lead programme from the Company’s ImmunoBody platform…

Early immune effect of SCIB1 observed by ImmunTraCkeR diagnostic

Industry news / 11 January 2016 / Victoria White

Cancer vaccine SCIB1 is a DNA ImmunoBody immunotherapy encoding a human IgG1 antibody, with three epitopes from gp100 and one from TRP-2 engineered into its CDR regions…

Scancell provides update on Phase 1/2 clinical trial of SCIB1 in Stage III/IV melanoma

Industry news / 2 June 2015 / Victoria White

Encouraging results have been announced from a Phase 1/2 trial of SCIB1, a DNA ImmunoBody being developed for the treatment of patients with melanoma…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+